Premium
CD34 + Stem Cell Therapy in Nonischemic Dilated Cardiomyopathy Patients
Author(s) -
Vrtovec B,
Poglajen G,
Sever M,
Lezaic L,
Socan A,
Haddad F,
Wu J C
Publication year - 2013
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2013.134
Subject(s) - dilated cardiomyopathy , medicine , cardiology , heart failure , cardiomyopathy , stem cell therapy , stem cell , cd34 , ischemic cardiomyopathy , transplantation , ejection fraction , biology , genetics
Recent trends indicate that patients with nonischemic dilated cardiomyopathy represent the largest subpopulation of heart failure patients with a significant need for alternative treatment modalities. Similar to patients with ischemic cardiomyopathy, patients with nonischemic dilated cardiomyopathy have been found to have myocardial regions with flow abnormalities, which may represent targets for neoangiogenic therapies. CD34 + stem cells might contribute to the formation of new blood vessels from existing vascular structures in ischemic tissues by the direct incorporation of injected cells into the newly developing vasculature or by the production and secretion of angiogenic cytokines. This review summarizes the long‐term clinical effects and potential underlying mechanisms of CD34 + cell therapy in patients with nonischemic dilated cardiomyopathy. Clinical Pharmacology & Therapeutics (2013); 94 4, 452–458. doi: 10.1038/clpt.2013.134